1. Home
  2. SJT vs ACTU Comparison

SJT vs ACTU Comparison

Compare SJT & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SJT
  • ACTU
  • Stock Information
  • Founded
  • SJT 1980
  • ACTU 2015
  • Country
  • SJT United States
  • ACTU United States
  • Employees
  • SJT N/A
  • ACTU N/A
  • Industry
  • SJT Oil & Gas Production
  • ACTU
  • Sector
  • SJT Energy
  • ACTU
  • Exchange
  • SJT Nasdaq
  • ACTU NYSE
  • Market Cap
  • SJT 181.8M
  • ACTU 153.1M
  • IPO Year
  • SJT N/A
  • ACTU 2024
  • Fundamental
  • Price
  • SJT $3.91
  • ACTU $6.74
  • Analyst Decision
  • SJT
  • ACTU
  • Analyst Count
  • SJT 0
  • ACTU 0
  • Target Price
  • SJT N/A
  • ACTU N/A
  • AVG Volume (30 Days)
  • SJT 241.1K
  • ACTU 73.4K
  • Earning Date
  • SJT 12-27-2024
  • ACTU 11-13-2024
  • Dividend Yield
  • SJT 3.17%
  • ACTU N/A
  • EPS Growth
  • SJT N/A
  • ACTU N/A
  • EPS
  • SJT 0.19
  • ACTU N/A
  • Revenue
  • SJT $11,031,594.00
  • ACTU N/A
  • Revenue This Year
  • SJT N/A
  • ACTU N/A
  • Revenue Next Year
  • SJT N/A
  • ACTU N/A
  • P/E Ratio
  • SJT $20.57
  • ACTU N/A
  • Revenue Growth
  • SJT N/A
  • ACTU N/A
  • 52 Week Low
  • SJT $3.21
  • ACTU $5.51
  • 52 Week High
  • SJT $5.81
  • ACTU $10.16
  • Technical
  • Relative Strength Index (RSI)
  • SJT 45.65
  • ACTU N/A
  • Support Level
  • SJT $3.78
  • ACTU N/A
  • Resistance Level
  • SJT $4.31
  • ACTU N/A
  • Average True Range (ATR)
  • SJT 0.16
  • ACTU 0.00
  • MACD
  • SJT -0.04
  • ACTU 0.00
  • Stochastic Oscillator
  • SJT 28.33
  • ACTU 0.00

About SJT San Juan Basin Royalty Trust

San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.

About ACTU ACTUATE THERAPEUTICS INC

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3β, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Share on Social Networks: